FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run
The May 1, 2026 approval of epdegestrant targets ESR1-mutated HR-positive metastatic breast cancer. Why genomic testing at relapse decides who qualifies.
Health News
Sector news category — verified health events only (FDA, guidelines, major studies)
FDA Approved Foundayo: the Oral GLP-1 That Rewrites Obesity Drug Economics
The April 1, 2026 approval of orforglipron brings GLP-1 weight-loss therapy to a daily tablet manufactured at standard scale. Efficacy, side effects, coverage.
FDA Approved Icotyde, Taking the Top Psoriasis Target From Injection to Pill
The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.
FDA Approved Bysanti: a New Antipsychotic for Schizophrenia and Bipolar I
The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.
CDC Moves to Align the Childhood Vaccine Schedule With Other Countries
A January 5, 2026 announcement tied to a presidential memorandum set off schedule changes, court challenges, and a postponed ACIP meeting. What parents should know.
FDA Approved Zycubo, the First Copper Therapy Cleared for Menkes Disease
The January 12, 2026 approval of copper histidinate gives infants with the rare ATP7A disorder a standardized, FDA-reviewed treatment option.